Peroxisome proliferator-activated receptor-γ agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution

Blood Purification

Volumn 24, Issue 5-6, 2006, Pages 575-582

  Yao, Qiang ^a,b   Pawlaczyk, Krzysztof ^a,c   Ayala, Ernesto Rodríguez ^a   Kuzlan, Malgorzata ^a,c   Styszynski, Arkadiusz ^c   Breborowicz, Andrzej ^c   Heimbürger, Olof ^a   Qian, Jiaqi ^b   Stenvinkel, Peter ^a   Axelsson, Jonas ^a   Lindholm, Bengt ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biocompatible solution; Fibrosis; Peritoneal dialysis; Peroxisome proliferator activated receptor agonist

Indexed keywords

COLLAGEN TYPE 1; DIANEAL; MISCELLANEOUS DRUGS AND AGENTS; PERITONEAL DIALYSIS FLUID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHYSIONEAL; ROSIGLITAZONE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BLOOD VOLUME; CONTROLLED STUDY; FLUID TRANSPORT; MALE; MORPHOLOGICAL TRAIT; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RAT; WISTAR RAT;

ANIMALS; HEMODIALYSIS SOLUTIONS; HYPOGLYCEMIC AGENTS; MALE; PERITONEAL DIALYSIS; PERITONEUM; PPAR GAMMA; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SMAD PROTEINS; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845947340     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097081     Document Type: Article

References (20)

1. Welten AG, Schalkwijk CG, ter Wee PM, et al: Single exposure of mesothelial cells to glucose degradation products yields early advanced glycation end-products and a proinflammatory response. Perit Dial Int 2003;23:213-221.
2. Zeier M, Schwenger V, Deppisch R, et al: Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298-305.
3. Locatelli F, Pozzoni P, Del Vecchio L: Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004;15(suppl 1):S25-S29.
4. Margetts PJ, Bonniaud P: Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003;23:530-541.
5. Witowski J, Korybalska K, Ksiazek K, et al: Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant 2004;19:917-924.
6. Krishnan M, Tam P, Wu G, et al: Glucose degradation products and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes? Int Urol Nephrol 2005;37:409-418.
7. Blake PG: Peritoneal dialysis in Asia: an external perspective. Perit Dial Int 2002;22:258-264.
8. Duman S, Gunal AI, Sen S, et al: Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2001;21:219-224.
9. Imai H, Nakamoto H, Ishida Y, et al: Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum. Adv Perit Dial 2001;17:20-24.
10. Yao Q, Nordfors L, Axelsson J, et al: Peroxisome proliferator-activated receptor-γ polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. Atherosclerosis 2005;182:105-111.
11. Jaster R, Lichte P, Fitzner B, et al: Peroxisome proliferator-activated receptor-γ overexpression inhibits pro-fibrogenic activities of immortalised rat pancreatic stellate cells. J Cell Mol Med 2005;9:670-682.
12. Wong TY, Szeto CC, Chow KM, et al: Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005;46:713-719.
13. Zheng F, Fornoni A, Elliot SJ, et al: Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPAR-γ activation. Am J Physiol Renal Physiol 2002;282:F639-F648.
14. Pawlaczyk K, Kuzlan-Pawlaczyk M, Wieczorowska-Tobis K, et al: Bicarbonate/lactate dialysis solution improves in vivo function of peritoneal host defense in rats. Perit Dial Int 1999;19(suppl 2):S370-S377.
15. Murata T, He S, Hangai M, et al: Peroxisome proliferator-activated receptor-γ ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:2309-2317.
16. Song J, Knepper MA, Hu X, et al: Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004;308:426-433.
17. Routh RE, Johnson JH, McCarthy KJ: Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 2002;61:1365-1376.
18. Chana RS, Lewington AJ, Brunskill NJ: Differential effects of peroxisome proliferator activated receptor-γ (PPAR-γ) ligands in proximal tubular cells: thiazolidinediones are partial PPAR-γ agonists. Kidney Int 2004;65:2081-2090.
19. Ghosh AK, Bhattacharyya S, Lakos G, et al: Disruption of transforming growth factor-β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor-γ. Arthritis Rheum 2004;50:1305-1318.
20. 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004;53:200-208.